bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S3 from Targeting Peroxisome Proliferator-Activated Receptor γ to Increase Estrogen-Induced Apoptosis in Estrogen-Deprived Breast Cancer Cells
Authors: Fan Ping , Abderrahman Balkees , Chai Tina S. , Yerrum Smitha , Jordan V. Craig
Published: April 2023

Modulation the expression of inflammatory factors by E2 and pioglitazone in breast cancer cell lines. A, MCF-7 cells were transferred from phenol red containing medium to E2-free medium for 3 days. Cells were then seeded in six-well plates. After 24 hours, cells were treated with a vehicle control (0.1% EtOH) or E2 (1 nM) for 24, 48, 72 hours. Cells were harvested in TRIzol reagent. TNFα expression levels were quantitated using RT-PCR. *P<0.05 compared with control; **P<0.001 compared with control. B, MCF-7:5C cells were treated with a vehicle control (0.1% EtOH+0.1% DMSO), E2 (1 nM), pioglitazone (10 µM), or a combination of them for 72 hours. Cells were then harvested in TRIzol reagent. LTB expression levels were quantitated using RT-PCR. *P<0.05 compared with control; **P<0.001 compared with control. C, MCF-7:2A cells were treated with a vehicle control (0.1% EtOH+0.1% DMSO), E2 (1 nM), pioglitazone (10 µM), or a combination of them for 9 days. Cells were then harvested in TRIzol reagent. LTB expression levels were quantitated using RT-PCR. *P<0.05 compared with control. D, MCF-7:5C cells were treated with a vehicle control (0.1% EtOH+0.1% DMSO), E2 (1 nM), pioglitazone (10 µM), or a combination of them for 72 hours. Cells were then harvested in TRIzol reagent. IL-6R expression levels were quantitated using RT-PCR. *P<0.05 compared with control; **P<0.001 compared with control. E, MCF-7:2A cells were treated with a vehicle control (0.1% EtOH+0.1% DMSO), E2 (1 nM), pioglitazone (10 µM), or a combination of them for 9 days. Cells were then harvested in TRIzol reagent. IL-6R expression levels were quantitated using RT-PCR. **P<0.001 compared with control. F, MCF-7:5C and MCF-7:2A cells were harvested for extraction of nuclear protein. NF-κB DNA binding activity was measured using a NF-κB (p65) transcription factor assay kit. *P<0.05 compared with control.
Supplementary Tables S1-S2 and Figures S1-S2 from Nano-Engineered Mesenchymal Stem Cells Increase Therapeutic Efficacy of Anticancer Drug Through True Active Tumor Targeting
Authors: Layek Buddhadev , Sadhukha Tanmoy , Panyam Jayanth , Prabha Swayam
Published: April 2023

Supplemental data file contains Table S1. Effect of different treatments on complete blood count, Table S2. Effect of different treatments on liver function test, Figure S1. In vitro migratory behavior of the nano-engineered MSCs, and Figure S2. Immunofluorescence staining of A549-luc cells.
Supplementary Fig 1 from Atovaquone: An Antiprotozoal Drug Suppresses Primary and Resistant Breast Tumor Growth by Inhibiting HER2/β-Catenin Signaling
Authors: Gupta Nehal , Srivastava Sanjay K.
Published: April 2023

Supplementary figure S1 shows the cytotoxicity of atovaquone in 4T1 and HEK293 cells.
Movie S7 from Targeting Polo-like Kinase 1 by a Novel Pyrrole-Imidazole Polyamide–Hoechst Conjugate Suppresses Tumor Growth In Vivo
Authors: Liu Ke , Fang Lijing , Sun Haiyan , Pan Zhengyin , Zhang Jianchao , Chen Juntao , Shao Ximing , Wang Wei , Tan Yuanyan , Ding Zhihao , Ao Lijiao , Wu Chunlei , Liu Xiaoqi , Li Huashun , Wang Rui , Su Wu , Li Hongchang
Published: April 2023

Live imaging of mitotic progression in control HUVEC cells
Movie S6 from Targeting Polo-like Kinase 1 by a Novel Pyrrole-Imidazole Polyamide–Hoechst Conjugate Suppresses Tumor Growth In Vivo
Authors: Liu Ke , Fang Lijing , Sun Haiyan , Pan Zhengyin , Zhang Jianchao , Chen Juntao , Shao Ximing , Wang Wei , Tan Yuanyan , Ding Zhihao , Ao Lijiao , Wu Chunlei , Liu Xiaoqi , Li Huashun , Wang Rui , Su Wu , Li Hongchang
Published: April 2023

Live imaging of mitotic progression in PIP3 treated hTERT-RPE1 cells
Movie S5 from Targeting Polo-like Kinase 1 by a Novel Pyrrole-Imidazole Polyamide–Hoechst Conjugate Suppresses Tumor Growth In Vivo
Authors: Liu Ke , Fang Lijing , Sun Haiyan , Pan Zhengyin , Zhang Jianchao , Chen Juntao , Shao Ximing , Wang Wei , Tan Yuanyan , Ding Zhihao , Ao Lijiao , Wu Chunlei , Liu Xiaoqi , Li Huashun , Wang Rui , Su Wu , Li Hongchang
Published: April 2023

Live imaging of mitotic progression in control hTERT-RPE1 cells
Supplementary Fig 2 from TSR-033, a Novel Therapeutic Antibody Targeting LAG-3, Enhances T-Cell Function and the Activity of PD-1 Blockade In Vitro and In Vivo
Authors: Ghosh Srimoyee , Sharma Geeta , Travers Jon , Kumar Sujatha , Choi Justin , Jun H. Toni , Kehry Marilyn , Ramaswamy Sridhar , Jenkins David
Published: April 2023

TSR-033 binding to LAG-3 by Surface Plasmon Resonance (SPR)
Movie S3 from Targeting Polo-like Kinase 1 by a Novel Pyrrole-Imidazole Polyamide–Hoechst Conjugate Suppresses Tumor Growth In Vivo
Authors: Liu Ke , Fang Lijing , Sun Haiyan , Pan Zhengyin , Zhang Jianchao , Chen Juntao , Shao Ximing , Wang Wei , Tan Yuanyan , Ding Zhihao , Ao Lijiao , Wu Chunlei , Liu Xiaoqi , Li Huashun , Wang Rui , Su Wu , Li Hongchang
Published: April 2023

Live imaging of mitotic progression in control A549 cells
Movie S2 from Targeting Polo-like Kinase 1 by a Novel Pyrrole-Imidazole Polyamide–Hoechst Conjugate Suppresses Tumor Growth In Vivo
Authors: Liu Ke , Fang Lijing , Sun Haiyan , Pan Zhengyin , Zhang Jianchao , Chen Juntao , Shao Ximing , Wang Wei , Tan Yuanyan , Ding Zhihao , Ao Lijiao , Wu Chunlei , Liu Xiaoqi , Li Huashun , Wang Rui , Su Wu , Li Hongchang
Published: April 2023

Live imaging of mitotic progression in PIP3 treated Hela cells
Table S1-S6 from APTO-253 Stabilizes G-quadruplex DNA, Inhibits MYC Expression, and Induces DNA Damage in Acute Myeloid Leukemia Cells
Authors: Local Andrea , Zhang Hongying , Benbatoul Khalid D. , Folger Peter , Sheng Xia , Tsai Cheng-Yu , Howell Stephen B. , Rice William G.
Published: April 2023

Primers, oligos, antibodies, and IC50 values.
Movie S1 from Targeting Polo-like Kinase 1 by a Novel Pyrrole-Imidazole Polyamide–Hoechst Conjugate Suppresses Tumor Growth In Vivo
Authors: Liu Ke , Fang Lijing , Sun Haiyan , Pan Zhengyin , Zhang Jianchao , Chen Juntao , Shao Ximing , Wang Wei , Tan Yuanyan , Ding Zhihao , Ao Lijiao , Wu Chunlei , Liu Xiaoqi , Li Huashun , Wang Rui , Su Wu , Li Hongchang
Published: April 2023

Live imaging of mitotic progression in control Hela cells.
Figure S8 In vivo antitumor activity of PIP3. from Targeting Polo-like Kinase 1 by a Novel Pyrrole-Imidazole Polyamide–Hoechst Conjugate Suppresses Tumor Growth In Vivo
Authors: Liu Ke , Fang Lijing , Sun Haiyan , Pan Zhengyin , Zhang Jianchao , Chen Juntao , Shao Ximing , Wang Wei , Tan Yuanyan , Ding Zhihao , Ao Lijiao , Wu Chunlei , Liu Xiaoqi , Li Huashun , Wang Rui , Su Wu , Li Hongchang
Published: April 2023

(a) Representative images of mice from vehicle group and PIP3-treated group on the sacrifice day. Yellow arrows indicate tumor locations. (b) Images of isolated tumors from vehicle group or PIP3-treated group. (c) In vivo cellular localization of PIP3. Frozen sections of tumors from PIP3-treated group were imaged under microscopy to visualize the cellular uptake of PIP3 in vivo. The nuclei were stained by Topro3. Scale bar, 100 μm.
Supplement Figure 2 from Auranofin Enhances Ibrutinib's Anticancer Activity in EGFR-Mutant Lung Adenocarcinoma
Authors: Hu Jing , Zhang Huijuan , Cao Mengru , Wang Li , Wu Shuhong , Fang Bingliang
Published: April 2023

Relative value of PARP cleavage based on intensity of Western blot bands of Figure 3. The value was determined using software ImageJ and normalized with β-actin.
Supplementary Table S1, Supplementary Table S2, Supplementary Table S3 from Phosphatidylinositol-3-kinase (PI3K)/Akt Signaling is Functionally Essential in Myxoid Liposarcoma
Authors: Trautmann Marcel , Cyra Magdalene , Isfort Ilka , Jeiler Birte , Krüger Arne , Grünewald Inga , Steinestel Konrad , Altvater Bianca , Rossig Claudia , Hafner Susanne , Simmet Thomas , Becker Jessica , Åman Pierre , Wardelmann Eva , Huss Sebastian , Hartmann Wolfgang
Published: April 2023

Supplementary Table S1: Clinicopathological characteristics of patients with myxoid liposarcoma (n=56) including semi-quantitative immunohistochemistry and mutational analyses results. Supplemental Table S2: Gene list. Supplementary Table S3: In silico tools to predict the deleterious impact of gene variants detected in myxoid liposarcoma.
Supplementary Figure S1 from Phosphatidylinositol-3-kinase (PI3K)/Akt Signaling is Functionally Essential in Myxoid Liposarcoma
Authors: Trautmann Marcel , Cyra Magdalene , Isfort Ilka , Jeiler Birte , Krüger Arne , Grünewald Inga , Steinestel Konrad , Altvater Bianca , Rossig Claudia , Hafner Susanne , Simmet Thomas , Becker Jessica , Åman Pierre , Wardelmann Eva , Huss Sebastian , Hartmann Wolfgang
Published: April 2023

Supplementary Figure S1: In vitro and in vivo evaluation of PI3K suppression (LY294002) in myxoid liposarcoma cell lines.
Figure S1 Effect of PIP3 on TNF-α induced IL6 and IL8 expression. from Targeting Polo-like Kinase 1 by a Novel Pyrrole-Imidazole Polyamide–Hoechst Conjugate Suppresses Tumor Growth In Vivo
Authors: Liu Ke , Fang Lijing , Sun Haiyan , Pan Zhengyin , Zhang Jianchao , Chen Juntao , Shao Ximing , Wang Wei , Tan Yuanyan , Ding Zhihao , Ao Lijiao , Wu Chunlei , Liu Xiaoqi , Li Huashun , Wang Rui , Su Wu , Li Hongchang
Published: April 2023

(a and b) A549 cells were treated with different concentrations of PIP2 or PIP3. After 72 h of treatment, cells were incubated with 10 ng/ml TNF-α for additional 12 h, and then harvested for IL6 (a) and IL8 (b) qRT-PCR analysis.
figure S2 from HIF2α-Targeted RNAi Therapeutic Inhibits Clear Cell Renal Cell Carcinoma
Authors: Wong So C. , Cheng Weijun , Hamilton Holly , Nicholas Anthony L. , Wakefield Darren H. , Almeida Aaron , Blokhin Andrei V. , Carlson Jeffrey , Neal Zane C. , Subbotin Vladimir , Zhang Guofeng , Hegge Julia , Bertin Stephanie , Trubetskoy Vladimir S. , Rozema David B. , Lewis David L. , Kanner Steven B.
Published: April 2023

RGD-PDC cellular uptake
Figure S5 from HIF2α-Targeted RNAi Therapeutic Inhibits Clear Cell Renal Cell Carcinoma
Authors: Wong So C. , Cheng Weijun , Hamilton Holly , Nicholas Anthony L. , Wakefield Darren H. , Almeida Aaron , Blokhin Andrei V. , Carlson Jeffrey , Neal Zane C. , Subbotin Vladimir , Zhang Guofeng , Hegge Julia , Bertin Stephanie , Trubetskoy Vladimir S. , Rozema David B. , Lewis David L. , Kanner Steven B.
Published: April 2023

SEAP
Figure S3 from HIF2α-Targeted RNAi Therapeutic Inhibits Clear Cell Renal Cell Carcinoma
Authors: Wong So C. , Cheng Weijun , Hamilton Holly , Nicholas Anthony L. , Wakefield Darren H. , Almeida Aaron , Blokhin Andrei V. , Carlson Jeffrey , Neal Zane C. , Subbotin Vladimir , Zhang Guofeng , Hegge Julia , Bertin Stephanie , Trubetskoy Vladimir S. , Rozema David B. , Lewis David L. , Kanner Steven B.
Published: April 2023

Integrin IHC
Figure S7 from Characterization of the Anti–PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice
Authors: Burova Elena , Hermann Aynur , Waite Janelle , Potocky Terra , Lai Venus , Hong Seongwon , Liu Matt , Allbritton Omaira , Woodruff Amy , Wu Qi , D’Orvilliers Amanda , Garnova Elena , Rafique Ashique , Poueymirou William , Martin Joel , Huang Tammy , Skokos Dimitris , Kantrowitz Joel , Popke Jon , Mohrs Markus , MacDonald Douglas , Ioffe Ella , Olson William , Lowy Israel , Murphy Andrew , Thurston Gavin
Published: April 2023

Concentration-time profile of REGN2810 in serum following a single intravenous infusion to cynomolgus monkeys.
Figure S1 from HIF2α-Targeted RNAi Therapeutic Inhibits Clear Cell Renal Cell Carcinoma
Authors: Wong So C. , Cheng Weijun , Hamilton Holly , Nicholas Anthony L. , Wakefield Darren H. , Almeida Aaron , Blokhin Andrei V. , Carlson Jeffrey , Neal Zane C. , Subbotin Vladimir , Zhang Guofeng , Hegge Julia , Bertin Stephanie , Trubetskoy Vladimir S. , Rozema David B. , Lewis David L. , Kanner Steven B.
Published: April 2023

Dose response
Figure S6 from Characterization of the Anti–PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice
Authors: Burova Elena , Hermann Aynur , Waite Janelle , Potocky Terra , Lai Venus , Hong Seongwon , Liu Matt , Allbritton Omaira , Woodruff Amy , Wu Qi , D’Orvilliers Amanda , Garnova Elena , Rafique Ashique , Poueymirou William , Martin Joel , Huang Tammy , Skokos Dimitris , Kantrowitz Joel , Popke Jon , Mohrs Markus , MacDonald Douglas , Ioffe Ella , Olson William , Lowy Israel , Murphy Andrew , Thurston Gavin
Published: April 2023

REGN2810 therapy enhances adaptive immune responses in vivo.
Table S1 from Monitoring Tumor Burden in Response to FOLFIRINOX Chemotherapy Via Profiling Circulating Cell-Free DNA in Pancreatic Cancer
Authors: Wei Tao , Zhang Qi , Li Xiang , Su Wei , Li Guogang , Ma Tao , Gao Shunliang , Lou Jianying , Que Risheng , Zheng Lei , Bai Xueli , Liang Tingbo
Published: April 2023

The list of 560 genes included in the panel.
Figure S4 from Characterization of the Anti–PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice
Authors: Burova Elena , Hermann Aynur , Waite Janelle , Potocky Terra , Lai Venus , Hong Seongwon , Liu Matt , Allbritton Omaira , Woodruff Amy , Wu Qi , D’Orvilliers Amanda , Garnova Elena , Rafique Ashique , Poueymirou William , Martin Joel , Huang Tammy , Skokos Dimitris , Kantrowitz Joel , Popke Jon , Mohrs Markus , MacDonald Douglas , Ioffe Ella , Olson William , Lowy Israel , Murphy Andrew , Thurston Gavin
Published: April 2023

Expression of human PD-1 on activated T cells from human PD-1 knock-in mice and expression of PD-L1 on MC38.Ova cells.
Figure S2 from Monitoring Tumor Burden in Response to FOLFIRINOX Chemotherapy Via Profiling Circulating Cell-Free DNA in Pancreatic Cancer
Authors: Wei Tao , Zhang Qi , Li Xiang , Su Wei , Li Guogang , Ma Tao , Gao Shunliang , Lou Jianying , Que Risheng , Zheng Lei , Bai Xueli , Liang Tingbo
Published: April 2023

Validation of KRAS hotspot mutation by Sanger sequencing in the tumor tissue in one case.
Figure S2 from Characterization of the Anti–PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice
Authors: Burova Elena , Hermann Aynur , Waite Janelle , Potocky Terra , Lai Venus , Hong Seongwon , Liu Matt , Allbritton Omaira , Woodruff Amy , Wu Qi , D’Orvilliers Amanda , Garnova Elena , Rafique Ashique , Poueymirou William , Martin Joel , Huang Tammy , Skokos Dimitris , Kantrowitz Joel , Popke Jon , Mohrs Markus , MacDonald Douglas , Ioffe Ella , Olson William , Lowy Israel , Murphy Andrew , Thurston Gavin
Published: April 2023

REGN2810 does not induce ADCC or CDC in either unstimulated or CD3/CD28 stimulated Jurkat cells.
Figure S1 from Monitoring Tumor Burden in Response to FOLFIRINOX Chemotherapy Via Profiling Circulating Cell-Free DNA in Pancreatic Cancer
Authors: Wei Tao , Zhang Qi , Li Xiang , Su Wei , Li Guogang , Ma Tao , Gao Shunliang , Lou Jianying , Que Risheng , Zheng Lei , Bai Xueli , Liang Tingbo
Published: April 2023

Quality control of extracted cfDNA and constructed library. Bioanalyzer analysis showing the size distribution of cfDNA (A) and corresponding constructed library (B). There was no genomic contamination in the cfDNA sample.
Supplementary Table from Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics
Authors: Choi In Sil , Kato Shumei , Fanta Paul T. , Leichman Lawrence , Okamura Ryosuke , Raymond Victoria M. , Lanman Richard B. , Lippman Scott M. , Kurzrock Razelle
Published: April 2023

Supplementary Table
Supplementary Figure from Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics
Authors: Choi In Sil , Kato Shumei , Fanta Paul T. , Leichman Lawrence , Okamura Ryosuke , Raymond Victoria M. , Lanman Richard B. , Lippman Scott M. , Kurzrock Razelle
Published: April 2023

Supplementary Figure
Supplemental Video 3 from Arginine Deprivation Therapy: Putative Strategy to Eradicate Glioblastoma Cells by Radiosensitization
Authors: Hinrichs C. Noreen , Ingargiola Mirjam , Käubler Theresa , Löck Steffen , Temme Achim , Köhn-Luque Alvaro , Deutsch Andreas , Vovk Olena , Stasyk Oleh , Kunz-Schughart Leoni A.
Published: April 2023

Representative video recording the invasion of cells from pre-treated U87-MG-shp53 spheroids into a 3-D collagen type I gel over a period of 18 h under chronic ADT conditions (-Arg). The spheroid diameter before embedding into the ECM-gel was 370-400 µm.
Supplemental Video 2 from Arginine Deprivation Therapy: Putative Strategy to Eradicate Glioblastoma Cells by Radiosensitization
Authors: Hinrichs C. Noreen , Ingargiola Mirjam , Käubler Theresa , Löck Steffen , Temme Achim , Köhn-Luque Alvaro , Deutsch Andreas , Vovk Olena , Stasyk Oleh , Kunz-Schughart Leoni A.
Published: April 2023

Representative video recording the invasion of cells from treated U87-MG-shp53 spheroids into a 3-D collagen type I gel over a period of 18 h ubder acute ADT conditions (-Arg). The spheroid diameter before embedding into the ECM-gel was 370-400 µm.
Supplemental Video 1 from Arginine Deprivation Therapy: Putative Strategy to Eradicate Glioblastoma Cells by Radiosensitization
Authors: Hinrichs C. Noreen , Ingargiola Mirjam , Käubler Theresa , Löck Steffen , Temme Achim , Köhn-Luque Alvaro , Deutsch Andreas , Vovk Olena , Stasyk Oleh , Kunz-Schughart Leoni A.
Published: April 2023

Representative video recording the invasion of cells from U87-MG-shp53 spheroids into a 3-D collagen type I gel over a period of 18 h under standard control conditions (+Arg). The spheroid diameter before embedding into the ECM gel was 370-400 µm.
Supplementary Figure 5 from Exploiting Radiation-Induced Signaling to Increase the Susceptibility of Resistant Cancer Cells to Targeted Drugs: AKT and mTOR Inhibitors as an Example
Authors: Eke Iris , Makinde Adeola Y. , Aryankalayil Molykutty J. , Sandfort Veit , Palayoor Sanjeewani T. , Rath Barbara H. , Liotta Lance , Pierobon Mariaelena , Petricoin Emanuel F. , Brown Matthew F. , Stommel Jayne M. , Ahmed Mansoor M. , Coleman C. Norman
Published: April 2023

Subcellular localization of AKT and mTOR after radiation. A, Western blots of mTOR, phospho-AKT S473 and AKT 2 h after 3 fractions of 2 Gy in 3D-grown PC3 cells after CRISPR/Cas9-mediated depletion of mTOR (crMTOR) using different targeting sequences. A non-targeting sequence (NTS) was used as control. β-actin expression was evaluated to ensure equal sample loading. B, Colony formation data of 3D colony formation assays. Cells were irradiated either with 6 Gy single dose or with 3 fractions of 2 Gy (2 Gy per day). Results show mean {plus minus} SD (n = 3, ** P < 0.01, Student''s t test). (See also Figure 6)
Supplementary figure 1 from Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma
Authors: Donson Andrew M. , Amani Vladimir , Warner Elliot A. , Griesinger Andrea M. , Witt Davis A. , Levy Jean M. Mulcahy , Hoffman Lindsey M. , Hankinson Todd C. , Handler Michael H. , Vibhakar Rajeev , Dorris Kathleen , Foreman Nicholas K.
Published: April 2023

Expression of EPN-selective drug targets in primary PFA patient samples versus cerebellum. Gene expression for (A) RARB, (B) PDGFRB, (C) VEGFR2 (KDR) and (D) VEGFC in twelve PFA patient samples and 4 pediatric cerebellum samples. Red bars represent mean and standard deviation. P-values = student's t-test.
Supplementary Figure 2 from Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma
Authors: Donson Andrew M. , Amani Vladimir , Warner Elliot A. , Griesinger Andrea M. , Witt Davis A. , Levy Jean M. Mulcahy , Hoffman Lindsey M. , Hankinson Todd C. , Handler Michael H. , Vibhakar Rajeev , Dorris Kathleen , Foreman Nicholas K.
Published: April 2023

Apoptosis time courses for EPN cell lines 811 and 928 treated with floxuridine, bexarotene, and axitinib all at 1µM, as measured by live cell imaging (IncuCyte) ofcaspase 3/7 activation (green objects/mm2). Idarubicin (1µM) provides a positive control for apoptosis and untreated cells serve as a negative control.
Figure S7 from Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance
Authors: Su Zhipeng , Han Yunchun , Sun Qichen , Wang Xiaoxiao , Xu Ting , Xie Wei , Huang Xing
Published: April 2023

Figure S7 shows the model of anti-MET VHH pool overcoming MET-targeted cancer therapeutic resistance.
Figure S6 from Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance
Authors: Su Zhipeng , Han Yunchun , Sun Qichen , Wang Xiaoxiao , Xu Ting , Xie Wei , Huang Xing
Published: April 2023

Figure S6 shows anti-MET VHH pool significantly inducing MET degradation.
Figure S4 from The XPO1 Inhibitor Selinexor Inhibits Translation and Enhances the Radiosensitivity of Glioblastoma Cells Grown In Vitro and In Vivo
Authors: Wahba Amy , Rath Barbara H. , O'Neill John W. , Camphausen Kevin , Tofilon Philip J.
Published: April 2023

Average weights of surviving mice in each treatment group.
Figure S4 from Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance
Authors: Su Zhipeng , Han Yunchun , Sun Qichen , Wang Xiaoxiao , Xu Ting , Xie Wei , Huang Xing
Published: April 2023

Figure S4 shows the long-term role of anti-MET VHH pool in treating mice.
Figure S2 from The XPO1 Inhibitor Selinexor Inhibits Translation and Enhances the Radiosensitivity of Glioblastoma Cells Grown In Vitro and In Vivo
Authors: Wahba Amy , Rath Barbara H. , O'Neill John W. , Camphausen Kevin , Tofilon Philip J.
Published: April 2023

Representative pictures of NSC11 cells stained for gH2AX (green) and Dapi (blue). Representative pictures of comet tails from NSC11 cells stained for SybrGreen (grey scale, full spectrum view).
Figure S3 from Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance
Authors: Su Zhipeng , Han Yunchun , Sun Qichen , Wang Xiaoxiao , Xu Ting , Xie Wei , Huang Xing
Published: April 2023

Figure S3 shows the efficacy of anti-MET VHH pool on tumor growth in individual mouse.
Figure S1 from The XPO1 Inhibitor Selinexor Inhibits Translation and Enhances the Radiosensitivity of Glioblastoma Cells Grown In Vitro and In Vivo
Authors: Wahba Amy , Rath Barbara H. , O'Neill John W. , Camphausen Kevin , Tofilon Philip J.
Published: April 2023

Effect of Selinexor on radiation-induced apoptosis
Supplementary Tables S1-4 from Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non–Small Cell Lung Cancer
Authors: Hirano Toshiyuki , Yasuda Hiroyuki , Hamamoto Junko , Nukaga Shigenari , Masuzawa Keita , Kawada Ichiro , Naoki Katsuhiko , Niimi Tatsuya , Mimasu Shinya , Sakagami Hideki , Soejima Kenzo , Betsuyaku Tomoko
Published: April 2023

Table S1:IC50 values of EGFR-TKIs for lung cancer cell lines. Table S2:IC50 values of EGFR-TKIs for Ba/F3 cells harboring EGFR exon 20 insertion mutations. Table S3:IC50 values of EGFR-TKIs for Ba/F3 cells harboring EGFR L858R or L858R+Y764_V765insHH. Table S4:Inhibitory effects of naquotinib on various kinases.
Supplementary Methods, Figures S1-S10, and Table S1 from Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1)
Authors: Sung Matthew , Tan Xingzhi , Lu Bingwen , Golas Jonathan , Hosselet Christine , Wang Fang , Tylaska Laurie , King Lindsay , Zhou Dahui , Dushin Russell , Myers Jeremy S. , Rosfjord Edward , Lucas Judy , Gerber Hans-Peter , Loganzo Frank
Published: April 2023

Supplementary Figure S1: N87 and N87-TM cells are similarly sensitive to unconjugated DM1-SMe; Supplementary Figure S2: Trastuzumab binding to N87 and N87-TM cells; Supplementary Figure S3: Generation and characterization of T-DM1-resistant HCC1954-TM and BT474-TM cells; Supplementary Figure S4: Relative resistance profiles of N87-TM to N87 cells to T-ADCs, unconjugated payloads and standard-of-care chemotherapeutics; Supplementary Figure S5: Distribution of T-ADCs in N87-TM tumors; Supplementary Figure S6: N87-TM cells are cross-resistant to a T-ADC conjugated to a cleavable linker with a cysteine-capped auristatin analog; Supplementary Figure S7: N87-TM cells internalize T-ADC into non-low pH intracellular compartments; Supplementary Figure S8: CAV1-GFP expression causes intracellular caveolae formation capable of internalizing T-ADCs in N87 cells; Supplementary Figure S9: CAV1 knockdown is not sufficient to re-sensitize N87-TM cells to T-DM1; Supplementary Figure S10: Non-cleavable and cleavable T-ADCs co-localize with CAV1 similarly in N87 and N87-TM cells; Supplementary Table S1. Cytotoxicity values of Trastuzumab and isotype-control ADCs in HT29 cells, a HER2-negative cell line
Supplementary Fig. S1, S2, S3, S4, S5 and S6. from TRP53 Mutants Drive Neuroendocrine Lung Cancer Through Loss-of-Function Mechanisms with Gain-of-Function Effects on Chemotherapy Response
Authors: Akeno Nagako , Reece Alisa L. , Callahan Melissa , Miller Ashley L. , Kim Rebecca G. , He Diana , Lane Adam , Moulton Jonathan S. , Wikenheiser-Brokamp Kathryn A.
Published: April 2023

Fig. S1 presents mutant Trp53 protein expression in lung tumors and metastases. Fig. S2 shows PTEN expression in lung tumors and metastases. Fig. S3 presents mTOR pathway inhibition by rapamycin in primary tumor cell cultures. Fig. S4 shows establishment of chemoresistant and chemosensitive primary cell cultures. Fig. S5 presents chemotherapeutic response of primary tumor cells derived from chemoresistant and chemosensitive lung tumors. Fig. S6 presents the effect of cisplatin and etoposide on cell growth of lung tumors in vitro.
Figure S3 from Cholesterol Depletion by TASIN-1 Induces Apoptotic Cell Death through the ER Stress/ROS/JNK Signaling in Colon Cancer Cells
Authors: Zhang Lu , Kim Sang Bum , Luitel Krishna , Shay Jerry W.
Published: April 2023

Supplementary Figure 2. TASIN-1 induces JNK pathway activation.
Figure S2 from Cholesterol Depletion by TASIN-1 Induces Apoptotic Cell Death through the ER Stress/ROS/JNK Signaling in Colon Cancer Cells
Authors: Zhang Lu , Kim Sang Bum , Luitel Krishna , Shay Jerry W.
Published: April 2023

Supplementary Figure 2.Blockage of protein translation rescues TASIN-1 induced cell death.
Supplementary Methods from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
Authors: Gomes Bruno , Driessens Gregory , Bartlett Derek , Cai Danying , Cauwenberghs Sandra , Crosignani Stefano , Dalvie Deepak , Denies Sofie , Dillon Christopher P. , Fantin Valeria R. , Guo Jie , Letellier Marie-Claire , Li Wenlin , Maegley Karen , Marillier Reece , Miller Nichol , Pirson Romain , Rabolli Virginie , Ray Chad , Streiner Nicole , Torti Vince R. , Tsaparikos Konstantinos , Van den Eynde Benoit J. , Wythes Martin , Yao Li-Chin , Zheng Xianxian , Tumang Joseph , Kraus Manfred
Published: April 2023

Supplementary Methods
Figure S3 from Inhibition of Parp1 by BMN673 Effectively Sensitizes Cells to Radiotherapy by Upsetting the Balance of Repair Pathways Processing DNA Double-Strand Breaks
Authors: Soni Aashish , Li Fanghua , Wang You , Grabos Martha , Krieger Lisa Marie , Chaudhary Shipra , Hasan Mohammad Sharif Mortoga , Ahmed Mansoor , Coleman C. Norman , Teicher Beverly A. , Piekarz Richard L. , Wang Dian , Iliakis George E.
Published: April 2023

BMN673 compromises repair of IR induced DSBs as measured by gamma H2AX foci fromation
Figure S1 from Inhibition of Parp1 by BMN673 Effectively Sensitizes Cells to Radiotherapy by Upsetting the Balance of Repair Pathways Processing DNA Double-Strand Breaks
Authors: Soni Aashish , Li Fanghua , Wang You , Grabos Martha , Krieger Lisa Marie , Chaudhary Shipra , Hasan Mohammad Sharif Mortoga , Ahmed Mansoor , Coleman C. Norman , Teicher Beverly A. , Piekarz Richard L. , Wang Dian , Iliakis George E.
Published: April 2023

(A) Inhibition of parylation by all Parpi tested. (B) Impact of BMN673 on radiosensitization in MEFs wt and PARP1-/- cells. (C) Short treatment with BMN673 suffices for maximum radiosensitivity.
Supplementary Figure 1 from Role of EphB3 Receptor in Mediating Head and Neck Tumor Growth, Cell Migration, and Response to PI3K Inhibitor
Authors: Bhatia Shilpa , Griego Anastacia , Lennon Shelby , Oweida Ayman , Sharma Jaspreet , Rohmer Christina , Uyanga Nomin , Bukkapatnam Sanjana , Van Court Benjamin , Raben David , Young Christian , Heasley Lynn , Karam Sana D.
Published: April 2023

Microarray analysis showing EphB3 levels in different tumor cell lines
Supplemental Table from Preclinical Evaluation of Nintedanib, a Triple Angiokinase Inhibitor, in Soft-tissue Sarcoma: Potential Therapeutic Implication for Synovial Sarcoma
Authors: Patwardhan Parag P. , Musi Elgilda , Schwartz Gary K.
Published: April 2023

List of antibodies with catalog numbers
Table S3 from TAS-114, a First-in-Class Dual dUTPase/DPD Inhibitor, Demonstrates Potential to Improve Therapeutic Efficacy of Fluoropyrimidine-Based Chemotherapy
Authors: Yano Wakako , Yokogawa Tatsushi , Wakasa Takeshi , Yamamura Keisuke , Fujioka Akio , Yoshisue Kunihiro , Matsushima Eiji , Miyahara Seiji , Miyakoshi Hitoshi , Taguchi Junko , Chong Khoon Tee , Takao Yayoi , Fukuoka Masayoshi , Matsuo Kenichi
Published: April 2023

Median survival times in a CFPAC-1 peritoneal dissemination model after S-1, TAS-114, or S-1 and TAS-114 combination treatment
Table S2 from TAS-114, a First-in-Class Dual dUTPase/DPD Inhibitor, Demonstrates Potential to Improve Therapeutic Efficacy of Fluoropyrimidine-Based Chemotherapy
Authors: Yano Wakako , Yokogawa Tatsushi , Wakasa Takeshi , Yamamura Keisuke , Fujioka Akio , Yoshisue Kunihiro , Matsushima Eiji , Miyahara Seiji , Miyakoshi Hitoshi , Taguchi Junko , Chong Khoon Tee , Takao Yayoi , Fukuoka Masayoshi , Matsuo Kenichi
Published: April 2023

Cytotoxicity effects of 5-FU, FdUrd, and paclitaxel in combination with TAS-114 in various human cancer cell lines
Supplemental Figure 2 from Preclinical Evaluation of Nintedanib, a Triple Angiokinase Inhibitor, in Soft-tissue Sarcoma: Potential Therapeutic Implication for Synovial Sarcoma
Authors: Patwardhan Parag P. , Musi Elgilda , Schwartz Gary K.
Published: April 2023

Cell proliferation assay on Day 6
Table S1 from TAS-114, a First-in-Class Dual dUTPase/DPD Inhibitor, Demonstrates Potential to Improve Therapeutic Efficacy of Fluoropyrimidine-Based Chemotherapy
Authors: Yano Wakako , Yokogawa Tatsushi , Wakasa Takeshi , Yamamura Keisuke , Fujioka Akio , Yoshisue Kunihiro , Matsushima Eiji , Miyahara Seiji , Miyakoshi Hitoshi , Taguchi Junko , Chong Khoon Tee , Takao Yayoi , Fukuoka Masayoshi , Matsuo Kenichi
Published: April 2023

X-ray crystallography data and refinement statistics
Figure S5 from TAS-114, a First-in-Class Dual dUTPase/DPD Inhibitor, Demonstrates Potential to Improve Therapeutic Efficacy of Fluoropyrimidine-Based Chemotherapy
Authors: Yano Wakako , Yokogawa Tatsushi , Wakasa Takeshi , Yamamura Keisuke , Fujioka Akio , Yoshisue Kunihiro , Matsushima Eiji , Miyahara Seiji , Miyakoshi Hitoshi , Taguchi Junko , Chong Khoon Tee , Takao Yayoi , Fukuoka Masayoshi , Matsuo Kenichi
Published: April 2023

Pharmacokinetic analysis of S-1 and TAS-114 combination in SD rats
Figure S2 from TAS-114, a First-in-Class Dual dUTPase/DPD Inhibitor, Demonstrates Potential to Improve Therapeutic Efficacy of Fluoropyrimidine-Based Chemotherapy
Authors: Yano Wakako , Yokogawa Tatsushi , Wakasa Takeshi , Yamamura Keisuke , Fujioka Akio , Yoshisue Kunihiro , Matsushima Eiji , Miyahara Seiji , Miyakoshi Hitoshi , Taguchi Junko , Chong Khoon Tee , Takao Yayoi , Fukuoka Masayoshi , Matsuo Kenichi
Published: April 2023

Enzyme kinetic analysis of human dUTPase inhibition by TAS-114 and calculation of Km and Ki values
Supplementary Materials and Methods, Figures S1 - S4 and Tables S1 - S3 from Unraveling the Interaction between Carboxylesterase 1c and the Antibody–Drug Conjugate SYD985: Improved Translational PK/PD by Using Ces1c Knockout Mice
Authors: Ubink Ruud , Dirksen Eef H.C. , Rouwette Myrthe , Bos Ebo S. , Janssen Ingrid , Egging David F. , Loosveld Eline M. , van Achterberg Tanja A. , Berentsen Kim , van der Lee Miranda M.C. , Bichat Francis , Raguin Olivier , van der Vleuten Monique A.J. , Groothuis Patrick G. , Dokter Wim H.A.
Published: April 2023

Figure S1: In vitro kinetics of SYD985. Total antibody concentration during 96-hour incubation of 100 mg/mL SYD985 at 37°C in human, monkey, rat and mouse plasma (mean +/- SEM). Figure S2: Ion trap MS/MS fragmentation spectrum (HCD @30 eV) of three SYD985-CES1c cross-linked peptide structures (all precursor ions were 3+) Figure S3: A, Conjugated antibody concentrations in female BALB/c mice after a single IV bolus injection of 1 and 5 mg/kg SYD985 in combination with an intraperitoneal injection of 150 mg/kg BNPP, 15 minutes prior to SYD985 dosing (mean +/- SEM, n=3). B, Conjugated antibody concentrations in female BALB/c mice after a single IV bolus injection of 5 mg/kg SYD985 in combination with increasing subcutaneous dosages of CBDP, 60 minutes prior to SYD985 dosing (mean +/- SEM, n=3). Figure S4: Anti-tumor activity of SYD985 compared to vehicle control in the breast cancer PDX models MAXF449. Table S1: ADC pharmacokinetic parameters in CES1c transgenic mice mice after a single i.v. bolus injection of 5 mg/kg SYD985. Table S2: IC50 and efficacy values of cytotoxic activity presented in Figure 1E. Table S3: Comparison of SYD985 conjugated antibody PK parameters in MAXF1162 tumor bearing CES1c -/- SCID mice with the PK in human.
Supplementary Naterials and Methods. Supplmentary Figures 1-6 from Targeting the Proteasome-Associated Deubiquitinating Enzyme USP14 Impairs Melanoma Cell Survival and Overcomes Resistance to MAPK-Targeting Therapies
Authors: Didier Robin , Mallavialle Aude , Ben Jouira Rania , Domdom Marie Angela , Tichet Mélanie , Auberger Patrick , Luciano Frédéric , Ohanna Mickael , Tartare-Deckert Sophie , Deckert Marcel
Published: April 2023

Supplementary Figure 1. b-AP15 and its derivative VLX1570 inhibit USP14 activity in melanoma cells. Supplementary Figure 2. USP14 inhibition irreversibly induces growth inhibition and cytotoxicity in melanoma cells. Supplementary Figure 3. USP14 overexpression reduces the cytotoxic effect of b-AP15 on melanoma cell. Supplementary Figure 4. siRNA-mediated depletion of USP14 reduces melanoma cell growth and focus formation. Supplementary Figure 5. USP14 targeting induces caspase-independent and ROS-dependent cell death. Supplementary Figure 6. USP14 inhibition induces a rapid accumulation of polyubiquitinated proteins and HSP70 in melanoma cells
Figure S1-S4 from Characterization of SGN-CD123A, A Potent CD123-Directed Antibody–Drug Conjugate for Acute Myeloid Leukemia
Authors: Li Fu , Sutherland May Kung , Yu Changpu , Walter Roland B. , Westendorf Lori , Valliere-Douglass John , Pan Lucy , Cronkite Ashley , Sussman Django , Klussman Kerry , Ulrich Michelle , Anderson Martha E. , Stone Ivan J. , Zeng Weiping , Jonas Mechthild , Lewis Timothy S. , Goswami Maitrayee , Wang Sa A. , Senter Peter D. , Law Che-Leung , Feldman Eric J. , Benjamin Dennis R.
Published: April 2023

Gating strategy, primary AML cytotoxicity assay,additional cell liens for pH2AX assay and caspase assay, and h7G3ec antibody sequence
Supplementary Figures 1-7 from Simultaneous Targeting of Two Distinct Epitopes on MET Effectively Inhibits MET- and HGF-Driven Tumor Growth by Multiple Mechanisms
Authors: Grandal Michael M. , Havrylov Serhiy , Poulsen Thomas T. , Koefoed Klaus , Dahlman Anna , Galler Gunther R. , Conrotto Paolo , Collins Sara , Eriksen Karsten W. , Kaufman Dafna , Woude George F.Vande , Jacobsen Helle J. , Horak Ivan D. , Kragh Michael , Lantto Johan , Bouquin Thomas , Park Morag , Pedersen Mikkel W.
Published: April 2023

Supplementary figure 1. Sym015 inhibits viability of cell lines in a synergic manner; Supplementary figure 2. The Sym015 antibodies Hu9338 and Hu9006 bind to 2nd or 3rd blades of MET and block HGF binding; Supplementary figure 3. Sym015 induces MET internalization and degradation in MKN-45 cells; Supplementary figure 4. Sym015 induces MET internalization and degradation in EBC-1 cells; Supplementary figure 5. Sym015 induces MET degradation in MKN-45 and EBC-1 cells; Supplementary figure 6. Sym015 inhibits signaling by MET in EBC-1 cells; Supplementary figure 7. Sym015 inhibits motility of EBC-1
Table S1 from Augmentation of Nab-Paclitaxel Chemotherapy Response by Mechanistically Diverse Antiangiogenic Agents in Preclinical Gastric Cancer Models
Authors: Awasthi Niranjan , Schwarz Margaret A. , Zhang Changhua , Schwarz Roderich E.
Published: April 2023

Characteristics of gastric cancer cell lines
Supplementary Figures S1 and S2 from Fluorouracil Enhances Photodynamic Therapy of Squamous Cell Carcinoma via a p53-Independent Mechanism that Increases Protoporphyrin IX levels and Tumor Cell Death
Authors: Anand Sanjay , Rollakanti Kishore R. , Brankov Nikoleta , Brash Douglas E. , Hasan Tayyaba , Maytin Edward V.
Published: April 2023

Figure S1. UVB-induced squamous cell carcinoma (SCC) of the skin, when treated with 5-FU, shows increased expression of the differentiation marker E-cadherin, relative to vehicle treatment alone. Figure S2. Pretreatment of cutaneous UVB-induced SCC with 5-FU prior to PDT causes enhanced tumor cell death, as measured by TUNEL and by H&E histological staining.
Figure S2 from Augmentation of Nab-Paclitaxel Chemotherapy Response by Mechanistically Diverse Antiangiogenic Agents in Preclinical Gastric Cancer Models
Authors: Awasthi Niranjan , Schwarz Margaret A. , Zhang Changhua , Schwarz Roderich E.
Published: April 2023

Mouse body weight in MKN-45 cell-derived subcutaneous xenografts (A) and in patient-derived xenografts (B). Mouse body weight was measured and presented as a bar chart during the therapy period.
Figure S1 from MicroRNA-203 Inhibits Long Noncoding RNA HOTAIR and Regulates Tumorigenesis through Epithelial-to-mesenchymal Transition Pathway in Renal Cell Carcinoma
Authors: Dasgupta Pritha , Kulkarni Priyanka , Majid Shahana , Shahryari Varahram , Hashimoto Yutaka , Bhat Nadeem S. , Shiina Marisa , Deng Guoren , Saini Sharanjot , Tabatabai Z. Laura , Yamamura Soichiro , Tanaka Yuichiro , Dahiya Rajvir
Published: April 2023

Knockdown of HOTAIR inhibits EMT
Supplementary Figure 4 from δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion
Authors: Shimizu Toshihiko , Ishida Joji , Kurozumi Kazuhiko , Ichikawa Tomotsugu , Otani Yoshihiro , Oka Tetsuo , Tomita Yusuke , Hattori Yasuhiko , Uneda Atsuhito , Matsumoto Yuji , Date Isao
Published: April 2023

WST-1 assay and two-chamber assay
Supplementary Table 3 from RAS–MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR–MEK Blockade
Authors: Bockorny Bruno , Rusan Maria , Chen Wankun , Liao Rachel G. , Li Yvonne , Piccioni Federica , Wang Jun , Tan Li , Thorner Aaron R. , Li Tianxia , Zhang Yanxi , Miao Changhong , Ovesen Therese , Shapiro Geoffrey I. , Kwiatkowski David J. , Gray Nathanael S. , Meyerson Matthew , Hammerman Peter S. , Bass Adam J.
Published: April 2023

Supplementary Table 3 shows top 2500 upregulated genes for each cluster utilized for pathway enrichment analysis.
Supplementary Table 1, 2 and 4 from RAS–MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR–MEK Blockade
Authors: Bockorny Bruno , Rusan Maria , Chen Wankun , Liao Rachel G. , Li Yvonne , Piccioni Federica , Wang Jun , Tan Li , Thorner Aaron R. , Li Tianxia , Zhang Yanxi , Miao Changhong , Ovesen Therese , Shapiro Geoffrey I. , Kwiatkowski David J. , Gray Nathanael S. , Meyerson Matthew , Hammerman Peter S. , Bass Adam J.
Published: April 2023

Supplementary Table 1 and 2 describe pharmacologic properties of BGJ398 and FIIN-3 and Supplementary Table 4 describes the characteristics of cellular models employed in the colony formation assays.
Supplement Methods from RAS–MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR–MEK Blockade
Authors: Bockorny Bruno , Rusan Maria , Chen Wankun , Liao Rachel G. , Li Yvonne , Piccioni Federica , Wang Jun , Tan Li , Thorner Aaron R. , Li Tianxia , Zhang Yanxi , Miao Changhong , Ovesen Therese , Shapiro Geoffrey I. , Kwiatkowski David J. , Gray Nathanael S. , Meyerson Matthew , Hammerman Peter S. , Bass Adam J.
Published: April 2023

Supplement Methods
Supplementary Materials and Methods from The TLR3 Agonist Inhibit Drug Efflux and Sequentially Consolidates Low-Dose Cisplatin-Based Chemoimmunotherapy while Reducing Side Effects
Authors: Ding Liang , Ren Jing , Zhang Dongya , Li Yi , Huang Xiaofeng , Ji Jianjian , Hu Qingang , Wang Hui , Ni Yanhong , Hou Yayi
Published: April 2023

Therapeutic protocols of tumor models and all other methods were described in Supplementary materials and methodsã€,
Figure S4 from RAS–MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR–MEK Blockade
Authors: Bockorny Bruno , Rusan Maria , Chen Wankun , Liao Rachel G. , Li Yvonne , Piccioni Federica , Wang Jun , Tan Li , Thorner Aaron R. , Li Tianxia , Zhang Yanxi , Miao Changhong , Ovesen Therese , Shapiro Geoffrey I. , Kwiatkowski David J. , Gray Nathanael S. , Meyerson Matthew , Hammerman Peter S. , Bass Adam J.
Published: April 2023

Figure S4 shows immunoblots of cells expressing a subset of resistance ORFs
Supplementary Table 1 from Characterizing the Potency and Impact of Carbon Ion Therapy in a Primary Mouse Model of Soft Tissue Sarcoma
Authors: Brownstein Jeremy M. , Wisdom Amy J. , Castle Katherine D. , Mowery Yvonne M. , Guida Peter , Lee Chang-Lung , Tommasino Francesco , Tessa Chiara La , Scifoni Emanuele , Gao Junheng , Luo Lixia , Campos Lorraine Da Silva , Ma Yan , Williams Nerissa , Jung Sin-Ho , Durante Marco , Kirsch David G.
Published: April 2023

Serial tumor volume measurements on individual mice. Absolute tumor volume in mm3 is shown for individual mice on each measurement day following irradiation (in treated mice) or once tumors reached 40 mm3 (in untreated controls). Measurements were taken until the predefined experiment endpoint.
Figure S2 and S3 from RAS–MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR–MEK Blockade
Authors: Bockorny Bruno , Rusan Maria , Chen Wankun , Liao Rachel G. , Li Yvonne , Piccioni Federica , Wang Jun , Tan Li , Thorner Aaron R. , Li Tianxia , Zhang Yanxi , Miao Changhong , Ovesen Therese , Shapiro Geoffrey I. , Kwiatkowski David J. , Gray Nathanael S. , Meyerson Matthew , Hammerman Peter S. , Bass Adam J.
Published: April 2023

Figure S2 shows ORF screen for resistance to FGFR inhibition and Figure S3 shows candidate mediators of resistance to FGFR inhibition based on ORF screen.
Supplementary Figure 2 from Characterizing the Potency and Impact of Carbon Ion Therapy in a Primary Mouse Model of Soft Tissue Sarcoma
Authors: Brownstein Jeremy M. , Wisdom Amy J. , Castle Katherine D. , Mowery Yvonne M. , Guida Peter , Lee Chang-Lung , Tommasino Francesco , Tessa Chiara La , Scifoni Emanuele , Gao Junheng , Luo Lixia , Campos Lorraine Da Silva , Ma Yan , Williams Nerissa , Jung Sin-Ho , Durante Marco , Kirsch David G.
Published: April 2023

Histological analyses at 24 and 48 hours. Data are from Figure 5 divided into discrete time point of tumor harvest. A) Percent Ki-67 positive. B) Percent phospho-histone H3 positive. C) Number of CD3 positive cells per high power field.
Supplemental Tables 1-3 and Supplemental Figure 1 from Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics
Authors: Ikeda Sadakatsu , Lim Jordan S. , Kurzrock Razelle
Published: April 2023

54, 68, and 70 gene panels; Oncoprint of 26 patients
Table S1 from MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents
Authors: McDaniel Nellie K. , Cummings Christopher T. , Iida Mari , Hülse Justus , Pearson Hannah E. , Vasileiadi Eleana , Parker Rebecca E. , Orbuch Rachel A. , Ondracek Olivia J. , Welke Noah B. , Kang Grace H. , Davies Kurtis D. , Wang Xiaodong , Frye Stephen V. , Earp H. Shelton , Harari Paul M. , Kimple Randall J. , DeRyckere Deborah , Graham Douglas K. , Wheeler Deric L.
Published: April 2023

Supplemental Antibodies list
Supplementary Figure S1 from Improving the In Vivo Efficacy of an Anti-Tac (CD25) Immunotoxin by Pseudomonas Exotoxin A Domain II Engineering
Authors: Kaplan Gilad , Mazor Ronit , Lee Fred , Jang Youjin , Leshem Yasmin , Pastan Ira
Published: April 2023

Illustrations of the rationally designed domain II truncation mutants
Supplemental Materials and Methods from MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents
Authors: McDaniel Nellie K. , Cummings Christopher T. , Iida Mari , Hülse Justus , Pearson Hannah E. , Vasileiadi Eleana , Parker Rebecca E. , Orbuch Rachel A. , Ondracek Olivia J. , Welke Noah B. , Kang Grace H. , Davies Kurtis D. , Wang Xiaodong , Frye Stephen V. , Earp H. Shelton , Harari Paul M. , Kimple Randall J. , DeRyckere Deborah , Graham Douglas K. , Wheeler Deric L.
Published: April 2023

Supplemental cell lines list
Figure S5 from MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents
Authors: McDaniel Nellie K. , Cummings Christopher T. , Iida Mari , Hülse Justus , Pearson Hannah E. , Vasileiadi Eleana , Parker Rebecca E. , Orbuch Rachel A. , Ondracek Olivia J. , Welke Noah B. , Kang Grace H. , Davies Kurtis D. , Wang Xiaodong , Frye Stephen V. , Earp H. Shelton , Harari Paul M. , Kimple Randall J. , DeRyckere Deborah , Graham Douglas K. , Wheeler Deric L.
Published: April 2023

Overexpression of TYRO3 does not confer resistance to AXL inhibition.
Figure S4 from MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents
Authors: McDaniel Nellie K. , Cummings Christopher T. , Iida Mari , Hülse Justus , Pearson Hannah E. , Vasileiadi Eleana , Parker Rebecca E. , Orbuch Rachel A. , Ondracek Olivia J. , Welke Noah B. , Kang Grace H. , Davies Kurtis D. , Wang Xiaodong , Frye Stephen V. , Earp H. Shelton , Harari Paul M. , Kimple Randall J. , DeRyckere Deborah , Graham Douglas K. , Wheeler Deric L.
Published: April 2023

AXL and MERTK inhibitors mediate synergistic inhibition of tumor cell expression in vitro.
Figure S2 from MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents
Authors: McDaniel Nellie K. , Cummings Christopher T. , Iida Mari , Hülse Justus , Pearson Hannah E. , Vasileiadi Eleana , Parker Rebecca E. , Orbuch Rachel A. , Ondracek Olivia J. , Welke Noah B. , Kang Grace H. , Davies Kurtis D. , Wang Xiaodong , Frye Stephen V. , Earp H. Shelton , Harari Paul M. , Kimple Randall J. , DeRyckere Deborah , Graham Douglas K. , Wheeler Deric L.
Published: April 2023

Inhibition of AXL upregulates MERTK expression and activity in additional cell culture models.
Figure S1 from MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents
Authors: McDaniel Nellie K. , Cummings Christopher T. , Iida Mari , Hülse Justus , Pearson Hannah E. , Vasileiadi Eleana , Parker Rebecca E. , Orbuch Rachel A. , Ondracek Olivia J. , Welke Noah B. , Kang Grace H. , Davies Kurtis D. , Wang Xiaodong , Frye Stephen V. , Earp H. Shelton , Harari Paul M. , Kimple Randall J. , DeRyckere Deborah , Graham Douglas K. , Wheeler Deric L.
Published: April 2023

Evaluation of AXL inhibitor R428.
Supplementary Figure S4 from Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness
Authors: Iavarone Claudia , Zervantonakis Ioannis K. , Selfors Laura M. , Palakurthi Sangeetha , Liu Joyce F. , Drapkin Ronny , Matulonis Ursula A. , Hallberg Dorothy , Velculescu Victor E. , Leverson Joel D. , Sampath Deepak , Mills Gordon B. , Brugge Joan S.
Published: April 2023

Supplementary Figure S4 shows the pilot assessment of efficacy of the GDC-0973 and ABT-263 combination and four-arms efficacy study in HGSOC PDX models